Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a strong-buy rating in a research report sent to investors on Saturday.

Other research analysts have also issued reports about the stock. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Bank of America restated an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Six equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Trading Up 4.9%

NASDAQ AMPH opened at $20.78 on Friday. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The business has a fifty day simple moving average of $19.66 and a 200 day simple moving average of $21.39. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $31.26. The firm has a market capitalization of $916.19 million, a P/E ratio of 12.30, a PEG ratio of 4.39 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.92%. The firm had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. On average, analysts predict that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AMPH. Deutsche Bank AG purchased a new stake in Amphastar Pharmaceuticals during the second quarter worth about $712,000. Bank of New York Mellon Corp purchased a new position in Amphastar Pharmaceuticals in the second quarter valued at about $4,689,000. State of Wyoming bought a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $142,000. Pacer Advisors Inc. grew its position in shares of Amphastar Pharmaceuticals by 47.1% during the 1st quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock valued at $5,122,000 after acquiring an additional 83,739 shares during the period. Finally, Segall Bryant & Hamill LLC grew its position in shares of Amphastar Pharmaceuticals by 197.9% during the 1st quarter. Segall Bryant & Hamill LLC now owns 33,318 shares of the company’s stock valued at $653,000 after acquiring an additional 22,133 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Key Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Amphastar reported second-quarter revenue of $183.9 million, exceeding analysts’ approximately $179.9 million estimate. Adjusted earnings were $0.91 per share, well above consensus estimates ranging from $0.62 to $0.66 and up from $0.85 a year earlier. GAAP net income totaled $30.3 million, or $0.67 per share, while adjusted net income was $40.8 million. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
• Positive Sentiment: The earnings beat was broad enough to attract attention from analysts, with coverage highlighting stronger-than-expected revenue, EPS and other key quarterly metrics. The results provide a positive near-term catalyst for AMPH and help support its valuation despite the stock remaining below its 200-day moving average. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Wells Fargo raised its price target from $19 to $20 but maintained an “equal weight” rating. The revised target remains below the recent trading level, signaling limited perceived upside despite the earnings performance. Wells Fargo price-target update
• Negative Sentiment: Piper Sandler lowered its price target from $21 to $20 and assigned a “neutral” rating. The downgrade in target suggests analysts remain cautious about AMPH’s outlook and could temper the positive reaction to the quarterly beat. Piper Sandler price-target update

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.